Al's Comment:

Very exciting news.  As I mentioned in a few previous posts (such as https://virtualtrials.org/newsarticle.cfm?item=6750) , the G47 Delta virus did remarkably well in a phase 2 trial for recurrent or residual Glioblastoma.  They reported a 1 year survival rate of 92% compared to historical controls of 15%.  This article says they applied for the Japanese equivalent of our FDA approval for it last month.   So at least in Japan, there will hopefully be a new, effective  Glioblastoma treatment soon. We have to work on getting it here in the USA.


Posted on: 01/06/2021

Daiichi Sankyo Submits Application for Oncolytic Virus Teserpaturev (G47 Delta) for Treatment of Patients with Malignant Glioma in Japan

 


Click HERE to return to brain tumor news headlines.